|

APRIL 1, 2015

Latham & Watkins and Davis Polk advise on Coherus BioSciences $120 million public offering

Latham & Watkins provided counsel to Redwood City-based biosimilar company Coherus BioSciences Inc. in its proposed $120 million public offering. The company is selling 4,137,931 shares of common stock at a price of $29 per share.

Menlo Park-based partner Alan Mendelson led the Latham team, with the help of associates Benjamin Potter, Owais Mahesri and Kevin Tsai. Partners Judith Hasko and James Metz and associate Lilly Fang also worked on the deal, along with San Francisco-based partner Grace M. L. Chen, counsel Betty Pang and associate Una Au. San Diego-based associate Vincent Chuang and Houston-based counsel Rebecca N. Brandt provided assistance.